NCT02625376.

Trial name or title	Resveratrol for exudative age‐related macular degeneration
Methods	Parallel group RCT
Participants	N = 489
Interventions	Dietary Supplement: Resvega Dietary Supplement: Trans‐Resveratrol Dietary Supplement: placebo
Outcomes	from clinical trials.gov "Primary Outcome Measures: Comparaison of incidence of choroidal neovascularization between resveratrol group and placebo group at 24 months (time frame: 24 months; designated as safety issue: Yes) What is the influence of the daily intake of 500 mg of resveratrol on the incidence of neovascularization of the second eye? Secondary Outcome Measures: Comparaison of incidence of choroidal neovascularization between Resvega group and placebo group at 24 months (time frame: 24 months; designated as safety issue: Yes) What is the influence of the daily intake resvega on the incidence of neovascularization of the second eye?"
Starting date	August 2015 to August 2019
Contact information	Nicolas LEVEZIEL, MD, Ph Dpt of Ophthalmology, University Hospital of Poitiers, France
Notes